Download Files:
LY2090314
$120 – $880
Products Details
Product Description
– LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.
Web ID
– HY-16294
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C28H25FN6O3
References
– [1]Atkinson JM, et al. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma–Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS One. 2015 Apr 27;10(4):e0125028.|[2]Zamek-Gliszczynski MJ, et al. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. Dr
CAS Number
– 603288-22-8
Molecular Weight
– 512.53
Compound Purity
– 99.78
SMILES
– O=C(C(C1=CN2CCN(C(N3CCCCC3)=O)CC4=CC(F)=CC1=C42)=C5C6=CN=C7C=CC=CN76)NC5=O
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– GSK-3
Isoform
– GSK-3α;GSK-3β
Pathway
– PI3K/Akt/mTOR;Stem Cell/Wnt
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
